Pharmaceutical giants have questioned why a waiver on intellectual property (IP) rights for COVID-19 vaccines is still on the table when they are battling to find markets for their vaccines amid order cancellations – including from the Africa Centre for Disease Control.  “I’m stunned that the proposed IP waiver is still being debated while supplies […] Continue reading ->
After years of being the neglected stepchild of global health, non-communicable diseases (NCDs) might finally be getting the urgent attention they need with Tuesday’s launch of an international NCD compact and presidential group. The measures were announced at the International Strategic Dialogue on NCDs and Sustainable Development Goals (SDGs) co-hosted by the governments of Ghana […] Continue reading ->
Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading ->